论文信息 - Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. - 字舞流文

Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.

P. Ascierto | R. Dummer | J. Wolchok | A. Bottomley | A. Eggermont | A. Testori | M. Smylie | H. Schmidt | J. Grob | V. Chiarion-Sileni | C. Robert | M. Maio | C. Lebbé | O. Hamid | J. Weber | C. Coens | S. Suciu | S. Kotapati | V. Ferraresi | J. Richards | V. de Pril | A. Eggermont | Alexander M M Eggermont